Posts by Moussa Mansour, MD
-
Pulsed Field Ablation Noninferior to Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation
Moussa Mansour, MD, and colleagues showed in the ADVENT registrational trial of the Farapulse system that among patients with atrial fibrillation, pulsed-field ablation was noninferior to conventional thermal ablation with respect to efficacy and device- and procedure-related serious adverse events within one year.
Biography
Moussa Mansour, MD, is Professor of Medicine at Harvard Medical School. He is also Director of the Atrial Fibrillation Program, and the Jeremy Ruskin and Dan Starks Endowed Chair in Cardiology, at Massachusetts General Hospital.
Dr. Mansour’s clinical and research interest focuses on atrial fibrillation and his aim is to enhance the understanding of this disease and improve the quality of care of patients suffering from it. He has pioneered the use of new techniques and technologies aiming at making ablation for atrial fibrillation safer and more effective.
Dr. Mansour is also an active clinical consultant in all aspects of heart rhythm disorders, including atrial fibrillation, ventricular tachycardia, supraventricular tachycardia, bradycardia and other abnormal rhythms. Dr. Mansour performs a large number of catheter ablation procedures and implants pacemakers and defibrillators to treat different arrhythmias.
Dr. Mansour has published extensively in the field of cardiac arrhythmia, specifically the area of atrial fibrillation. He is involved in cutting edge research and participates in the development of new catheters and techniques for the ablation of atrial fibrillation. Most recently he has been heavily involved in investigating pulsed-field ablation for atrial fibrillation, which is novel technology that has the potential to make ablation for atrial ablation safer and more effective.
In addition to catheter ablation, Dr. Mansour is an expert in the occlusion of the left atrial appendage using tools such as the Watchman devices for stroke prevention in patients with atrial fibrillation. He is involved in studies investigating new generations of this device that are safer and more effective.